We are live on ! Find out more
II

Ishara Investments Portfolio holdings

AUM $136M
This Fund
S&P 500
This Quarter Est. Return
+1.21%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$106M
AUM Growth
+$18.2M
Cap. Flow
+$18.5M
Cap. Flow %
17.55%
Top 10 Hldgs %
50.89%
Holding
56
New
18
Increased
10
Reduced
9
Closed
19

Top Buys

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$7.08M
2
KALV
KalVista Pharmaceuticals
KALV
+$4.46M
3
VERA icon
Vera Therapeutics
VERA
+$3.53M
4
ARWR icon
Arrowhead Research
ARWR
+$3.5M
5
VSTM icon
Verastem
VSTM
+$3.39M

Top Sells

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$5.4M
2
NUVB icon
Nuvation Bio
NUVB
+$3.58M
3
ANNX icon
Annexon
ANNX
+$3.24M
4
BBIO icon
BridgeBio Pharma
BBIO
+$2.75M
5
UTHR icon
United Therapeutics
UTHR
+$2.68M

Sector Composition

Rank Sector Weight
1 Healthcare 93.75%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NKTR icon
51
Nektar Therapeutics
NKTR
$2.52B
– –
-20,000
Closed -$846K
NUVB icon
52
Nuvation Bio
NUVB
$2.44B
– –
-400,000
Closed -$3.58M
OLMA icon
53
Olema Pharmaceuticals
OLMA
$949M
– –
-30,000
Closed -$750K
SNDX icon
54
Syndax Pharmaceuticals
SNDX
$1.79B
– –
-100,000
Closed -$2.1M
TARS icon
55
Tarsus Pharmaceuticals
TARS
$3.1B
– –
-24,000
Closed -$1.97M
UTHR icon
56
United Therapeutics
UTHR
$22.2B
– –
-5,500
Closed -$2.68M
1 2
3

Similar funds

SB
Semitam Bonam Goshen, New York $136M AUM 13.42% 1-Year Est. Return
WFA
WJ Financial Advisors Killingworth, Connecticut $136M AUM 23.45% 1-Year Est. Return
RC
Rahlfs Capital Lake Kiowa, Texas $136M AUM 33.89% 1-Year Est. Return
GBFP
Golden Bell Financial Planning Alpharetta, Georgia $136M AUM 12.99% 1-Year Est. Return
RIA
Rhodes Investment Advisors Fort Worth, Texas $136M AUM
RCWM
Red Crane Wealth Management San Francisco, California $136M AUM 18.56% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $136M AUM
HMS
Hanseatic Management Services Albuquerque, New Mexico $136M AUM

Ishara Investments's Q1 2026 Portfolio in Review

As of Q1 2026, Ishara Investments held 56 positions worth $106M, up 21% from $87.5M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Ishara Investments deployed $18.5M of net new capital in Q1 2026, opening 18 new positions and adding to 10 existing holdings. Its largest new stake was Axsome Therapeutics: 41,000 shares worth $6.93M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 96% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Praxis Precision Medicines, an estimated $5.4M trimmed.

  • Ishara Investments's largest Q1 2026 buy was Axsome Therapeutics: 41,000 shares worth $6.93M.
  • Ishara Investments added most to Verastem in Q1 2026, an estimated $3.39M increase.
  • Ishara Investments's biggest Q1 2026 reduction was Praxis Precision Medicines, cutting an estimated $5.4M.
  • Ishara Investments fully exited Nuvation Bio in Q1 2026, selling an estimated $3.58M.
  • Ishara Investments's ten largest holdings make up 51% of its $106M portfolio in Q1 2026.
  • Ishara Investments opened 18 new positions and closed 19 in Q1 2026.
  • Ishara Investments's portfolio value rose 21% quarter-over-quarter to $106M.

Based on Ishara Investments's 13F filing for Q1 2026, filed 15 May 2026.